Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85 % w/w API particles; 15-30 % w/w coating material coating the API particles; and 3-15 % w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60 % relative humidity.
1. A method of preparing a pharmaceutical composition comprising:
coating API particles with a coating material to form coated API particles, wherein the coating material comprises one or more deformable components;
applying mechanical stress to the coated API particles to deform the one or more deformable components;
dry coating the coated API particles with silica to provide a protective hydrophobic barrier layer to the coating material;
applying mechanical stress to at least one of adhere, partially embed, or embed the silica on the coated API particles;
after applying mechanical stress to the API particles coated with silica, sieving the coated API particles to remove excess coating material, wherein the excess coating material comprises coating material not bound to a coated API particle;
mixing the coated API particles into a matrix solution/suspension to form a pharmaceutical suspension; and
dosing the pharmaceutical suspension into a mold.
2. The method of claim 1 , wherein a dosing ratio used to combine the coated API particles with the matrix solution/suspension comprises 5-60% w/w coated API particles and 40-96% w/w matrix solution/suspension.
3. The method of claim 2 , wherein a coating ratio used to combine the API particles with the coating material comprises 5-85% w/w coating material and 15-95% w/w uncoated API particles.
4. The method of claim 1 , comprising freezing the dosed suspension under sub-zero conditions and freeze-drying to form a lyophilized pharmaceutical composition.
5. The method of claim 1 , further comprising sieving uncoated API particles.
6. The method of claim 1 , wherein sieving the coated API particles comprises passing the coated API particles through a device comprising two or more sieves.
7. The method of claim 1 , wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 75 μm or greater.
8. The method of claim 1 , wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 200 μm or less.
9. The method of claim 1 , wherein the API particles comprise one or more of anti-inflammatories, analgesics, anti-psychotics, anti-emetics, laxatives, anti-diarrheals, anti-histamines, or anti-depressants.
10. The method of claim 1 , wherein the coating material comprises silica as one or more of a protective coating or a flow aid.
11. The method of claim 1 , wherein the one or more deformable components of the coating material comprises a wax.
12. The method of claim 1 , wherein the wax comprises one or more of carnauba wax, candelilla wax, or synthetic wax.
13. The method of claim 1 , wherein the matrix solution/suspension comprises a matrix former and a structure former.
14. The method of claim 13 , wherein the matrix former comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.
15. The method of claim 13 , wherein the matrix former comprises a polypeptide.
16. The method of claim 14 , wherein the polypeptide comprises gelatin.
17. The method of claim 13 , wherein the structure former comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.
18. The method of claim 13 , wherein the structure former comprises mannitol.